为协同抗动脉样硬化疗法提供ROS响应的产药米塞尔联合交付系统
Qingfa Tang1, Yao Chen1, Yusheng Zhang1
1Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics, School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, P.R. China.
Molecular pharmaceutics
|July 31, 2023
概括
这项研究开发了一种新型的ROS响应性小细胞,用于联合输送Tanshinone IIA (TS-IIA) 和盐酸A (SAA) 来对抗动脉样硬化. 菌根体表现出协同作用的抗动脉样硬化作用,显示出有效治疗的希望.
科学领域:
- 生物材料科学 生物材料科学
- 药理学 药理学是指药理学的学科.
- 心血管研究研究心血管研究
背景情况:
- 坦辛IIA (TS-IIA) 和沙酸A (SAA) 是丹申的关键活性化合物,具有抗动脉样硬化特性.
- 它们的不同溶解度对协同交付带来了挑战.
- 开发有效的输送系统对于提高它们的治疗潜力至关重要.
研究的目的:
- 制造一种对ROS有反应的前药菌细胞 (TS-IIA-PM),用于共同提供TS-IIA和SAA.
- 评估TS-IIA-PM系统的稳定性,安全性和抗动脉样硬化疗效.
- 为了研究联合输送的TS-IIA和SAA的协同抗动脉样硬化作用.
主要方法:
- 制造一个对ROS有反应的两类块共聚合物微粒 (PEG5000-SAA/PLA10000-APBA).
- 使用1H NMR,FTIR和阿利沙林红色S竞争试验对聚合物的表征.
- 通过体外和体外研究评估细胞稳定性,ROS响应性,药物释放,生物相容性和抗动脉样作用.
主要成果:
- TS-IIA-PM微粒已经成功地制造和表征.
- 菌体在血清中表现出极好的稳定性和对ROS的反应性.
- 在体外和体外研究证实了TS-IIA-PM的协同抗动脉样作用和安全性.
结论:
- 开发的ROS响应性前药菌细胞 (TS-IIA-PM) 能够有效地同时提供TS-IIA和SAA.
- TS-IIA-PM 显示出显著的协同作用的抗动脉样硬化作用.
- 该系统具有安全有效的动脉样硬化治疗的巨大潜力.
相关概念视频
Prodrugs
2.7K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.7K
Drug Delivery: Overview
323
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
323
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
215
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
215


